Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Timolumab, an antibody targeting AOC3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rivabazumab, an antibody targeting PcrV type III secretion system.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rinucumab, an antibody targeting PDGFRB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Refanezumab, an antibody targeting SIGLEC4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Opicinumab, an antibody targeting LINGO1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Muromonab, an antibody targeting CD3E.

2026 Mycobacterium abscessus infection indication strategy covering epidemiology, ATP synthase biology, active trials, transactions, unmet need, competition and…

2026 Mycobacterium avium complex lung disease indication strategy covering epidemiology, ATP synthase biology, active trials, transactions, unmet need,…

2026 Pneumocystis jirovecii pneumonia indication strategy covering epidemiology, DHFR biology, active trials, transactions, unmet need, competition and market…

2026 Talaromycosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Sporotrichosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Blastomycosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.